A citation-based method for searching scientific literature


List of co-cited articles
120 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study.
James B Meigs, David M Nathan, Ralph B D'Agostino, Peter W F Wilson. Diabetes Care 2002
388
16




Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
12

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
12





Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.
M Hanefeld, S Fischer, U Julius, J Schulze, U Schwanebeck, H Schmechel, H J Ziegelasch, J Lindner. Diabetologia 1996
701
12




Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Ildiko Lingvay, Federico Pérez Manghi, Pedro García-Hernández, Paul Norwood, Lucine Lehmann, Mads Jeppe Tarp-Johansen, John B Buse. JAMA 2016
113
9

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Vanita R Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami,[...]. Diabetes Care 2016
122
9

The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.
Véronique Gingras, Nadine Taleb, Amélie Roy-Fleming, Laurent Legault, Rémi Rabasa-Lhoret. Diabetes Obes Metab 2018
36
9




Postprandial glucose regulation and diabetic complications.
Antonio Ceriello, Markolf Hanefeld, Lawrence Leiter, Louis Monnier, Alan Moses, David Owens, Naoko Tajima, Jaakko Tuomilehto. Arch Intern Med 2004
245
9

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.
Lutz Heinemann, Marcus Hompesch, Frank Flacke, Patrick Simms, Rody Pohl, Kerstin Albus, Andreas Pfützner, Solomon Steiner. J Diabetes Sci Technol 2011
21
14



Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin.
Anders H Boss, Richard Petrucci, Daniel Lorber. J Diabetes Sci Technol 2012
38
9

Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Chantal Mathieu, Bruce W Bode, Edward Franek, Athena Philis-Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell-Jones. Diabetes Obes Metab 2018
44
9




Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.
Itamar Raz, Antonio Ceriello, Peter W Wilson, Chakib Battioui, Eric W Su, Lisa Kerr, Cate A Jones, Zvonko Milicevic, Scott J Jacober. Diabetes Care 2011
59
9

The pros and cons of diagnosing diabetes with A1C.
Enzo Bonora, Jaakko Tuomilehto. Diabetes Care 2011
190
9

Postprandial hyperglycemia and glycemic variability: should we care?
Eberhard Standl, Oliver Schnell, Antonio Ceriello. Diabetes Care 2011
120
9

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
6

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
6

Glucose variability.
F John Service. Diabetes 2013
117
6

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
6

4. Lifestyle Management.
. Diabetes Care 2017
146
6

Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study.
Ajenthen Ranjan, Signe Schmidt, Camilla Damm-Frydenberg, Isabelle Steineck, Trine Ryberg Clausen, Jens Juul Holst, Sten Madsbad, Kirsten Nørgaard. Diabetes Care 2017
29
6

Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis.
Catherine Gorst, Chun Shing Kwok, Saadia Aslam, Iain Buchan, Evangelos Kontopantelis, Phyo K Myint, Grant Heatlie, Yoon Loke, Martin K Rutter, Mamas A Mamas. Diabetes Care 2015
218
6

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
160
6


Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
H W Rodbard, J B Buse, V Woo, T Vilsbøll, I H Langbakke, K Kvist, S C L Gough. Diabetes Obes Metab 2016
21
9

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
John B Buse, Tina Vilsbøll, Jerry Thurman, Thomas C Blevins, Irene H Langbakke, Susanne G Bøttcher, Helena W Rodbard. Diabetes Care 2014
161
6

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson. Diabetes Ther 2017
62
6


IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
Jens J Holst, John B Buse, Helena W Rodbard, Sultan Linjawi, Vincent C Woo, Trine Welløv Boesgaard, Kajsa Kvist, Stephen C Gough. J Diabetes Sci Technol 2015
14
14

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
Stewart B Harris, Győző Kocsis, Rudolf Prager, Terry Ridge, Keval Chandarana, Natalie Halladin, Serge Jabbour. Diabetes Obes Metab 2017
33
6

Exercise management in type 1 diabetes: a consensus statement.
Michael C Riddell, Ian W Gallen, Carmel E Smart, Craig E Taplin, Peter Adolfsson, Alistair N Lumb, Aaron Kowalski, Remi Rabasa-Lhoret, Rory J McCrimmon, Carin Hume,[...]. Lancet Diabetes Endocrinol 2017
297
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.